Response to chemotherapy improves hepatic reserve for patients with hepatocellular carcinoma and Child–Pugh B cirrhosis

フォーマット:

論文

責任表示:

Terashima, Takeshi ; Yamashita, Tatsuya ; Arai, Kuniaki ; Kawaguchi, Kazunori ; Kitamura, Kazuya ; Yamashita, Taro ; Sakai, Yoshio ; Mizukoshi, Eishiro ; Honda, Masao ; Kaneko, Shuichi

言語:

英語

出版情報:

Japanese Cancer Association / Blackwell Publishing Ltd, 2016-09-01

著者名:

Terashima, Takeshi

Yamashita, Tatsuya

Arai, Kuniaki

Kawaguchi, Kazunori

Kitamura, Kazuya

Yamashita, Taro

Sakai, Yoshio

Mizukoshi, Eishiro

Honda, Masao

Kaneko, Shuichi

続きを見る

掲載情報:

Cancer Science

ISSN:

1347-9032      

巻:

107

通号:

9

開始ページ:

1263

終了ページ:

1269

バージョン:

publisher

概要:

There is no established treatment for patients with advanced hepatocellular carcinoma (HCC) with Child–Pugh class B cirrhosis. The aim of the present study was to assess the efficacy of hepatic arterial infusion chemotherapy (HAIC) according to Child–Pugh score (CPS) and to evaluate the correlation of a patient's response to HAIC with hepatic reserve and outcome. We retrospectively reviewed the medical records of 377 patients treated with HAIC … between March 2003 and February 2015. Subjects included 179 with Child–Pugh class B. Median overall survival was 12.1 months for patients with CPS = 7 (n = 75) and 11.9 months for patients with CPS = 8 (n = 58), which were significantly longer compared with those of patients with CPS = 9 (n = 46, 6.3 months). The objective response rates of patients with CPS = 7, 8 and 9 were 26.7%, 27.6% and 6.5%, respectively. The CPS of responders improved significantly after HAIC, whereas those of nonresponders did not. A multivariate analysis demonstrated that improved CPS, responses to HAIC and absence of extrahepatic lesions were independent favorable prognostic factors. Patients with CPS = 7 or 8 tolerated HAIC, but nine (19.6%) of patients with CPS = 9 were unable to complete one course. HAIC is effective and safe for patients with a CPS = 7 or 8 and improved hepatic reserve of responders significantly. © 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. 続きを見る

URL:

http://hdl.handle.net/2297/46176